From bench to bedside: The hurdles of discovering a new leukotriene receptor antagonist

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 II, 2000, Pages

  Rodger, Ian W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLSULFONYL] 3 OXO 4 PHENYLBUTYRIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO]PHENYL] 4 HYDROXY 3 METHYLBUTYRIC ACID; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PRANLUKAST; SLOW REACTING SUBSTANCE; TOMELUKAST; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHODILATATION; CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG INDUSTRY; HUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS;

EID: 0034109835     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_1.ltta-2     Document Type: Review

References (32)

1. Feldberg, W., and C. H. Kellaway. 1938. Liberation of histamine and formation of lyscithin-like substances by cobra venom. J. Physiol. 94: 187-226.
2. Feldberg, W., H. F. Holden, and C. H. Kellaway. 1938. The formation of lyscithin and of a muscle-stimulating substance by snake venoms. J. Physiol. 94:232-248.
3. Kellaway, C. H., and E. R. Trethewie. 1940. The liberation of a slow reacting smooth-muscle stimulating substance in anaphylaxis. Q. J. Exp. Physiol. 30:121-145.
4. Brocklehurst, W. E. 1960. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J. Physiol. 151:416-435.
5. Murphy, R. C., S. Hammarstrom, and B. Samuelsson. 1979. Leukotriene C. A slow reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. U.S.A. 76:4275-4279.
6. Dahlen, S.-E., P. Hedqvist, S. Hammarstrom, and S. Samuelsson. 1980. Leukotrienes are potent constrictors of human bronchi. Nature (London) 288:484-486.
7. Friedman, B. C., E. H. Bel, A. Buntinx, W. Tanaka, Y. H. R. Han, S. Shingo, R. Spector, and P. J. Sterk. 1993. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis. 147:839-844.
8. Diamant, Z., M. C. Timmers, H. van der Veen, B. C. Friedman, M. DeSmet, M. Depre, D. Milliard, E. H. Bel, and P. J. Sterk. 1995. The effect of MK-0591, a novel 5-lipoxygcnase activating protein (FLAP) inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin. Immunol. 95:42-51.
9. Israel, E., P. Rubin, J. P. Kemp, J. Grossman, W. Pierson, S. C. Siegel, D. Tinkelman, J. J. Murray, W. W. Busse, A. T. Segal, et al. 1993. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Intern. Med. 119:1059-1066.
10. Rokach, J., Y. Girard, Y. Guindon, J. G. Atkinson, M. Larue, R. N. Young, P. Masson, and G. Holme. 1980. The synthesis of a leukotriene with SRS-like activity. Tetrahedron Lett. 21:1485-1488.
11. Corey, E. J., D. A. Clark, G. Goto, A. Marfat, C. Mioskowski, B. Samuelsson, and S. Hammarstrom. 1980. Stereospecific total synthesis of a "slow-reacting substance" of anaphylaxis, leukotriene C-I. J. Am. Chem. Soc. 102:1436-1439.
12. Augstein, J., J. B. Farmer, T. B. Lee, P. Sheard, and M. L. Tattersall. 1973. Selective inhibitor of slow reacting substance of anaphylaxis. Nature (London) 245:215-217.
13. 4 induced bronchoconstriction in normal man. J. Allergy Clin. Immunol. 79:816-821.
14. 4 antagonist L-649,923 on the response to inhaled antigen in asthma. J. Allergy Clin. Immunol. 79:811-816.
15. Evans, J. M., N. C. Barnes, J. T. Zakrzewski, D. G. Sciberras, E. G. Stahl, P. J. Piper, and J. F. Costello. 1989. L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man. Br. J. Clin. Pharmacol. 28:125-135.
16. Bel, E. H., M. C. Timmers, J. H. Dijkman, E. G. Stahl, and P. J. Sterk. 1990. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J. Allergy Clin. Immunol. 85:1067-1075.
17. 4 induced bronchoconstriction by p.o. administration of LY-171,883 in non-asthmatic subjects. J. Pharmac. Exp. Ther. 246:732-738.
18. 4 antagonist LY-171,883 on inhaled and intradermal challenge with antigen and LTD4 in atopic subjects. J. Allergy Clin, Immunol. 83:939-944.
19. 4) receptor antagonist (MK-571) in patients with asthma. Am. Rev. Respir. Dis. 146:358-363.
20. Rasmussen, J. B., L. O. Eriksson, D. J. Margolskee, P. Tagari, V. C. Williams, and K. E. Andersson. 1992. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin. Immunol. 90:193-201.
21. 4-receptor antagonist. N. Engl. J. Med. 323:1736-1739.
22. Taylor, I. K., K. M. O'Shaughnessy, R. W. Fuller, and C. T. Dollery. 1991. Effect of cysteinyl-leukotriene receptor antagonist ICI-204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694.
23. 4 receptor antagonist, MK-0679. Am. Rev. Respir. Dis. 147: 1442-1446.
24. Dahlen, B., M. Kumlin, D. J. Margolskee, C. Larsson, H. Blomqvist, V. C. Williams, O. Zetterstrom, and S.-E. Dahlen. 1993. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin sensitive asthmatics. Eur. Respir. J. 6:1018-1026.
25. Dahlen, B., D. J. Margolskee, O. Zetterstrom, and S.-E. Dahlen. 1993. Effect of the leukotrienc receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 48: 1205-1210.
26. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 73:191-201.
27. Reiss, T. F., C. A. Sorkness, W. Stricker, A. Botto, and W. W. Busse. 1997. Effects of montelukast (MK-0476), a potent cysteinyl-leukofriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52:45-48.
28. 4) receptor antagonist, in patients with chronic asthma. J. Allergy Clin. Immunol. 98:528-534.
29. Reiss, T. F., P. Chervinsky, R. J. Dockhorn, S. Shingo, B. C. Seidenberg. and T. B. Edwards. 1998. Montelukast, a once daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch. Intern. Med. 158:1213-1220.
30. Knorr, B. A., J. Matz, J. Bernstein, H. H. Nguyen, B. C. Seidenberg, T. F. Reiss, and A. Beeker. 1998. Montelukast for chronic asthma in 6-to 14-year-old patients: a randomised, double-blind trial. J. Amer. Med. Assoc. 297:1181-1186.
31. Leff, J. A., W. W. Busse, D. Pearlman, E. A. Bronsky, J. P. Kemp, L. Hendeles, R. J. Doekhorn, S. Kundu, J. Zhang, B. C. Seidenberg, and T. F. Reiss. 1998. Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New Engl. J. Med. 339:147-152.
32. Kemp, J. P., R. J. Dockhorn, G. G. Shapiro, H. H. Nguyen, T. F. Reiss, B. C. Seidenberg, and B. A. Knorr. 1998. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-to 14-year old children with asthma. J. Paediatr. 133:424-428.